Evidence map›Paper›PMID 36100684›Full record

ArticleScientific reports2022

Factors, associated with elevated concentration of soluble carbonic anhydrase IX in plasma of women with cervical dysplasia.

Švitrigailė Grincevičienė, Daiva Vaitkienė, Daiva Kanopienė, Rasa Vansevičiūtė, Jan Tykvart, Artūras Sukovas, Joana Celiešiūtė, Ernesta Ivanauskaitė Didžiokienė, Arvydas Čižauskas, Aida Laurinavičienė and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 2 countries.

Švitrigailė GrincevičienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania. svitrigaile.grinceviciene@bti.vu.lt.
Daiva VaitkienėDepartment of Obstetrics and Gynecology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu st. 2, 50161, Kaunas, Lithuania.
Daiva KanopienėConsultative Polyclinic Department, National Cancer Institute, Santariskiu st. 1, 08406, Vilnius, Lithuania.
Rasa VansevičiūtėConsultative Polyclinic Department, National Cancer Institute, Santariskiu st. 1, 08406, Vilnius, Lithuania.
Jan TykvartDiana Biotechnologies, Nad Safinou II 366, 252 50, Vestec, Czech Republic.
Artūras SukovasDepartment of Obstetrics and Gynecology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu st. 2, 50161, Kaunas, Lithuania.
Joana CeliešiūtėDepartment of Obstetrics and Gynecology, Medical Academy, Lithuanian University of Health Sciences, Eiveniu st. 2, 50161, Kaunas, Lithuania.
Ernesta Ivanauskaitė DidžiokienėNational Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, P. Baublio st. 5, 08406, Vilnius, Lithuania.
Arvydas ČižauskasDepartment of Pathological Anatomy, Medical Academy, Lithuanian University of Health Sciences, Eiveniu st. 2, 50161, Kaunas, Lithuania.
Aida LaurinavičienėNational Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, P. Baublio st. 5, 08406, Vilnius, Lithuania.
Vlastimil KrálInstitute of Molecular Genetics of the Czech Academy of Sciences, Flemingovo n. 2, 166 37, Prague 6, Czech Republic.
Anna HlavačkováInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo náměstí 542/2, 160 00, Praha, Czech Republic.
Jitka ZemanováDiana Biotechnologies, Nad Safinou II 366, 252 50, Vestec, Czech Republic.
Dovilė StravinskienėDepartment of Immunology and Cell Biology, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Aistė SližienėDepartment of Immunology and Cell Biology, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Agnė PetrošiūtėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Vytautas PetrauskasDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Renata BalsytėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Jonas GrincevičiusPharmacy Center, Institute of Biomedical Science, Faculty of Medicine, Vilnius University, M. K. Ciurlionio st. 21, 03101, Vilnius, Lithuania.
Vaclav NavratilDiana Biotechnologies, Nad Safinou II 366, 252 50, Vestec, Czech Republic.
Ullrich JahnInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo náměstí 542/2, 160 00, Praha, Czech Republic.
Jan KonvalinkaDiana Biotechnologies, Nad Safinou II 366, 252 50, Vestec, Czech Republic.
Aurelija ŽvirblienėDepartment of Immunology and Cell Biology, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Daumantas MatulisDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Jurgita MatulienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio sl. 7, 10257, Vilnius, Lithuania.
Vilnius University · LTLithuanian University of Health Sciences · LTCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZNational Cancer Institute · LTCzech Academy of Sciences, Institute of Molecular Genetics · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precancerous lesions of human cervix uteri have a tendency for regression or progression. In cervical intraepithelial neoplasia grade 2 (CINII) case there is an uncertainty if a lesion will progress or regress. The carbonic anhydrase IX (CAIX) enzyme is overexpressed in cervical cancer which is more sensitive to radiotherapy. CAIX is associated with poor prognosis in solid hypoxic tumors. The aim of this study was to determine factors related to elevated soluble CAIX (s-CAIX) in high-grade intraepithelial lesion (HSIL) cases.

methodsPatients diagnosed with HSIL (N = 77) were included into the research group whereas without HSIL (N = 72)-the control group. Concentration of the soluble CAIX (s-CAIX) in plasma was determined by the DIANA ligand-antibody-based method. C. trachomatis was detected from cervical samples by PCR. Primary outcomes were risk factors elevating s-CAIX level in HSIL group. Non-parametric statistical analysis methods were used to calculate correlations.

resultsThe s-CAIX level in patients with HSIL was elevated among older participants (r

conclusionThe concentration of s-CAIX was higher among older, heavy smoking and diagnosed with C. trachomatis patients. All these factors increased the risk for HSIL progression.

Indexed as

Carbonic AnhydrasesUterine Cervical DysplasiaUterine Cervical NeoplasmsAgedAntigens, NeoplasmCarbonic Anhydrase IXFemaleHumansAntigens, NeoplasmCA9 protein, humanCarbonic Anhydrase IXCarbonic Anhydrases

Identifiers

PMID36100684
PMCPMC9470728
OpenAlexW4295752127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.